Conclusion
In the real world, PCSK-9 inhibitors combined with statins could
significantly reduce LDL levels and risk of cardiovascular events among
patients with very high risk of ASCVD.
Key words: PCSK-9 inhibitor; Real world; LDL-c; Cardiovascular
events